疫苗政策的科学依据:对2025年9月ACIP流程、审议与投票的独立审查
该文由前ACIP投票成员分析2025年9月ACIP会议,使用标准化工具评估发现ACIP政策制定成熟度评分从2025年4月至9月的100%降至58%。会议存在透明度违规、政策问题表述不当、未系统应用GRADE等标准协议,委员会投票推荐COVID-19疫苗共享临床决策、限制联合第一剂MMRV疫苗可及性并推迟乙肝疫苗出生剂次投票。结论提出四项关切限制ACIP制定有效疫苗政策建议的能力。
要点
- 2025年4月至9月ACIP政策制定成熟度评分从100%降至58%。
- 2025年9月会议存在多项透明度违规,包括会前排除具备疫苗实施医学专业知识的联络组织。
- 委员会投票推荐COVID-19疫苗共享临床决策、限制联合第一剂MMRV疫苗可及性并推迟乙肝疫苗出生剂次投票。
核心结论
- 已出现四项关切限制ACIP为美国制定有效疫苗政策建议的能力:取消先前推荐疫苗的选择从而限制改善健康的机会;使用低质量数据关注理论上的疫苗危害;丧失疫苗科学与临床实践专业知识;透明度与独立性降低。
研究设计与样本
- 本文由前ACIP投票成员对2025年9月ACIP会议进行分析,使用标准化工具评估国家疫苗咨询小组的发展与功能以考察ACIP政策制定成熟度,并分析所呈现的证据、流程与疫苗建议。
主要发现
- 2025年4月至9月期间,ACIP政策制定成熟度评分从总体100%降至58%。
- 2025年9月会议存在多项透明度违规,包括会前排除具备疫苗实施医学专业知识的联络组织。
- 政策问题表述不当,随后缺乏对标准协议(如GRADE方法与证据到建议框架)的系统应用。
- 委员会投票推荐COVID-19疫苗共享临床决策、限制联合第一剂MMRV疫苗可及性并推迟移除乙肝疫苗出生剂次的投票。
- 讨论反映对流程理解不足、对科学掌握不充分,并聚焦于低质量安全性数据,排除疫苗政策制定公认的组成部分与标准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since 1964, the Advisory Committee on Immunization Practices (ACIP) has shaped US vaccine policy but recently underwent significant structural and procedural changes affecting recommendation quality. This paper presents analyses of the September 2025 ACIP meeting by former ACIP voting members. METHODS: We examined ACIP policymaking maturity using a standardized tool for assessing national vaccine advisory groups' development and functionality. We also analyzed evidence presented, processes, and vaccine recommendations. RESULTS: Between April and September 2025, ACIP's policymaking maturity rating fell from an overall score of 100 % to 58 %. The September meeting had multiple transparency violations, including the exclusion of liaison organizations with medical expertise in vaccine implementation before the meeting. Poorly framed policy questions were followed by a lack of systematic application of standard protocols (e.g., GRADE methodology and Evidence to Recommendations framework). The committee voted to recommend shared clinical decision making for COVID-19 vaccines, to limit access to combined first dose MMRV vaccines, and to postpone voting on removing the birth dose of hepatitis B vaccine. Discussions reflected poor understanding of process, inadequate grasp of science, and a focus on low-quality safety data, excluding well-recognized components and standards for vaccine policy making. CONCLUSIONS: Four concerns have emerged that limit ACIP's ability to make effective vaccine policy recommendations for the US: 1) removal of choice for previously recommended vaccines, thereby limiting opportunities to improve health, 2) focus on theoretical vaccine harms using low-quality data, 3) loss of vaccine science and clinical practice expertise, and 4) reduced transparency and independence.
引用
- Asturias EJ, Chen LH, Shaw AC, et al. Science for vaccine policy: Independent review of the September 2025 ACIP processes, deliberations and votes. Vaccine. 2025. PMID: 41135287. doi:10.1016/j.vaccine.2025.127876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。